Table 1 Patient characteristics
From: Significance of day-to-day glucose variability in patients after acute coronary syndrome
Characteristic | N = 25 |
|---|---|
Age (years) | 69.7 ± 10.9 |
Males (%) | 21 (84.0) |
Risk factors | |
DM (%) | 8 (32) |
Smoking (%) | 9 (36) |
BMI (kg/m2) | 23.1 ± 3.31 |
HT (%) | 18 (72) |
Previous CAD (%) | 2 (8) |
CKD (%) | 11 (44) |
DLP (%) | 6 (24) |
Medications | |
Antiplatelet drug (%) | 5 (20) |
Beta-blocker (%) | 1 (4) |
ACE-I/ARB (%) | 11(44) |
CCB (%) | 10 (40) |
Statin (%) | 6 (24) |
Anti-hyperuricemic drug (%) | 3 (12) |
Oral antidiabetes drug (%) | 7 (28) |
Blood tests | |
TG, mg/dl | 103.7 ± 54.0 |
LDL, mg/dl | 98.32 ± 36.3 |
HDL, mg/dl | 44.6 ± 9.7 |
1-5 AG, μg/ml | 16.7 ± 8.6 |
apoA-I, mg/dl | 105.2 ± 16.5 |
apoB, mg/dl | 75.3 ± 23.1 |
apoE, mg/dl | 2.8 ± 0.85 |
DHLA, μg/ml | 33.7 ± 12.1 |
AA, μg/ml | 166.6 ± 41.8 |
EPA, μg/ml | 58.5 ± 42.4 |
DHA, μg/ml | 119.3 ± 48.3 |
EPA/AA | 0.35 ± 0.22 |
NT-proBNP, pg/ml | 2032.0 ± 2063.3 |
MDA-LDL, U/l | 80.3 ± 29.6 |
peakCK, U/l | 1310.1 ± 1293.0 |
HbA1c, % | 6.23 ± 0.70 |
Type of ACS | |
STEMI (%) | 14 (56) |
Non-STEMI (%) | 6 (24) |
UAP (%) | 5 (20) |